Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications

Journal of the American Heart Association

Volumn 4, Issue 3, 2015, Pages e001897-

  Alfredsson, Joakim ^a   Roe, Matthew T ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

arteriosclerosis; Editorials; platelets; prevention; thrombin

Indexed keywords

ANTITHROMBOCYTIC AGENT; LACTONE; PROTEINASE ACTIVATED RECEPTOR 1; PYRIDINE DERIVATIVE;

ANTAGONISTS AND INHIBITORS; DRUG APPROVAL; FEMALE; HUMAN; MALE; MYOCARDIAL INFARCTION; PERIPHERAL ARTERIAL DISEASE; PROCEDURES; SECONDARY PREVENTION;

DRUG APPROVAL; FEMALE; HUMANS; LACTONES; MALE; MYOCARDIAL INFARCTION; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECEPTOR, PAR-1; SECONDARY PREVENTION;

EID: 85006667209     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.115.001897     Document Type: Editorial

References (0)